Literature DB >> 23771728

Evaluation of a heredofamilial cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital.

Iván Márquez-Rodas1, Sara López-Tarruella, Yolanda Jerez, Mercedes Cavanagh, Sara Custodio, Daniel López-Trabada, Beatriz Moya, Sara Pérez, Ana B Rupérez, Miguel Martín.   

Abstract

A comprehensive family history is essential to identify patients at risk for hereditary cancer who could benefit from genetic counseling (GC). In a previous study, we observed a low occurrence of family history record (FHR) collection rate and GC referral among oncologists at our institution. The present work analyzes whether the implementation of a heredofamilial cancer unit (HFCU) would improve these parameters. We retrospectively compared the FHR rate in clinical records, National Cancer Institute (NCI) general criteria for hereditary cancer suspicion, GC referrals and FHR quality in two cohorts: cohort 1 (patients diagnosed before HFCU creation) and cohort 2 (after HFCU creation). Of 1,175 patients (590 cohort 1 and 585 cohort 2), FHRs were consigned in 27.3 % and 52.5 % of patients, respectively (p < 0.001). The GC referral of patients with any NCI criterion was 13.6 % xin cohort 1 vs. 40.5 % in cohort 2 (p < 0.001). FHR quality improved in terms of the total number of relatives (164 vs. 314, p = 0.1, N.S.) and number of healthy relatives consigned (80 vs. 191, p < 0.01). Nine mutations (6 BRCA, 1 MEN1, 2 Lynch), 4 unknown significance variants (all in BRCA) and 2 with no mutation were identified among patients referred from cohort 2. We conclude that the creation of a heredofamilial cancer unit has changed both FHR and GC referrals among oncologists at our institution, although continuous educational efforts are required.

Entities:  

Mesh:

Year:  2013        PMID: 23771728     DOI: 10.1007/s10897-013-9617-z

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  18 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.

Authors:  Bhramar Mukherjee; John Oliver Delancey; Leon Raskin; Jessica Everett; Joanne Jeter; Colin B Begg; Irene Orlow; Marianne Berwick; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Hoda Anton Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Lynn From; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2012-04-24       Impact factor: 13.506

Review 3.  Hereditary colon cancer syndromes.

Authors:  Manish Gala; Daniel C Chung
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

4.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

5.  Identification and referral of families at high risk for cancer susceptibility.

Authors:  Kevin M Sweet; Terry L Bradley; Judith A Westman
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

Review 6.  Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine.

Authors:  Jeffrey N Weitzel; Kathleen R Blazer; Deborah J MacDonald; Julie O Culver; Kenneth Offit
Journal:  CA Cancer J Clin       Date:  2011-08-19       Impact factor: 508.702

Review 7.  Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors.

Authors:  Angela Trepanier; Mary Ahrens; Wendy McKinnon; June Peters; Jill Stopfer; Sherry Campbell Grumet; Susan Manley; Julie O Culver; Ronald Acton; Joy Larsen-Haidle; Lori Ann Correia; Robin Bennett; Barbara Pettersen; Terri Diamond Ferlita; Josephine Wagner Costalas; Katherine Hunt; Susan Donlon; Cecile Skrzynia; Carolyn Farrell; Faith Callif-Daley; Catherine Walsh Vockley
Journal:  J Genet Couns       Date:  2004-04       Impact factor: 2.537

Review 8.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

9.  Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.

Authors:  Marie E Wood; Pamela Kadlubek; Trang H Pham; Dana S Wollins; Karen H Lu; Jeffrey N Weitzel; Michael N Neuss; Kevin S Hughes
Journal:  J Clin Oncol       Date:  2014-02-03       Impact factor: 44.544

10.  Family history-taking in community family practice: implications for genetic screening.

Authors:  L S Acheson; G L Wiesner; S J Zyzanski; M A Goodwin; K C Stange
Journal:  Genet Med       Date:  2000 May-Jun       Impact factor: 8.822

View more
  2 in total

1.  The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review.

Authors:  Jennifer N Eichmeyer; Christa Burnham; Patty Sproat; Rick Tivis; Thomas M Beck
Journal:  J Genet Couns       Date:  2013-10-25       Impact factor: 2.537

2.  Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.

Authors:  Miriam Lobo; Sara López-Tarruella; Soledad Luque; Santiago Lizarraga; Carmen Flores-Sánchez; Oscar Bueno; Jesús Solera; Yolanda Jerez; Ricardo González Del Val; María Isabel Palomero; María Cebollero; Isabel Echavarría; Gabriela Torres; Miguel Martín; Iván Márquez-Rodas
Journal:  J Genet Couns       Date:  2017-12-15       Impact factor: 2.537

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.